Ausbiz Capital is now SureStone Capital. Same team, same ABN and AFS authorisations.

ASX: CXOCore Lithium LtdMaterials

Core Lithium Extends Blackbeard Hit to 74m @ 1.32% Li2O

Core Lithium's final NMRD108 assays at Blackbeard extend the intersection to 74.0m @ 1.32% Li2O from 209m, with estimated true thickness of approximately 43m.

By Digifin Pty Ltd · About this coverage

Key Points

  • NMRD108 final assays extend the intersection to 74.0m @ 1.32% Li2O from 209m
  • Estimated true thickness of the NMRD108 intersection is approximately 43m
  • NMRD110 returned 76.7m @ 0.77% Li2O from 63.3m, including 21.7m @ 1.28% Li2O
  • Blackbeard lies less than 20km from the Finniss processing plant
Core Lithium Ltd (ASX:CXO)

About Core Lithium (ASX:CXO)

Core Lithium Ltd is an ASX-listed lithium company with its registered office in Perth. Its principal asset is the Finniss Lithium Operation near Darwin in the Northern Territory, a hard-rock spodumene project. The company also holds exploration tenements for other minerals in the Northern Territory.

Core Lithium (ASX:CXO) released final assays for hole NMRD108 at the Blackbeard prospect, extending a previously reported partial intersection and adding to the drilling it is using to assess Blackbeard as a source of additional resources for the Finniss Lithium Operation.

Final results extended the NMRD108 intersection from 29m @ 1.35% Li2O to 74.0m @ 1.32% Li2O from 209m, within a 96m pegmatite intersection. This is a downhole length; the company estimates true thickness at approximately 43m. Core says it is the second-longest downhole mineralised intersection at Blackbeard to date, after NMRD104 (92m @ 1.25% Li2O from 92m), and lies approximately 50m along strike from SRC117. NMRD110, drilled approximately 90m west-northwest of NMRD108, returned 76.7m @ 0.77% Li2O from 63.3m, including 21.7m @ 1.28% Li2O from 63.3m and 6m @ 1.20% Li2O from 114m. NMRD106 intersected a single narrow pegmatite returning 1m @ 0.90% Li2O from 406.2m. Blackbeard is less than 20km from the Finniss processing plant, and the staged and gated diamond drilling campaign totals 12,150m.

These are Exploration Results, not a Mineral Resource. The true thickness of the NMRD110 intersection cannot yet be estimated with confidence. Core says resource definition at Blackbeard may support assessment of plant throughput above the current 1.2Mtpa base case, but no study outcome or decision is reported.

Back to all ASX Company News

Source: Core Lithium Ltd (ASX:CXO), 6 November 2026. Summary content supplied by Digifin Pty Ltd.

News summary only, not financial advice. It does not consider your objectives, financial situation or needs.

Friday, 6 November 2026

Also summarised today

All ASX Company News
ASX: AVHHealth Care

AVITA Medical Raises 2026 Revenue Guidance to $92m-$94m

AVITA Medical's Q3 revenue rose 53% to approximately $26.1 million, and the company raised its full-year 2026 revenue guidance to $92 million to $94 million.

6 Nov, 8:26 am AEDT
ASX: IVZEnergy

Invictus Begins Musuma-1 Rig-Up in Zimbabwe

Invictus Energy has started rig-up and well services mobilisation for Musuma-1 in Zimbabwe, with spud on track for November 2026 subject to equipment arrival.

6 Nov, 9:13 am AEDT
ASX: JHXMaterials

James Hardie Q2 FY27 Sales Up 24%, Lifts Cash Flow Target

James Hardie's Q2 continuing net sales rose 24% to US$1,428.2 million; it reaffirmed FY27 guidance and raised its free cash flow target to more than US$650m.

6 Nov, 8:12 am AEDT
ASX: JINConsumer Discretionary

Jumbo Interactive Reaffirms FY27 Guidance at AGM

Jumbo Interactive reaffirmed FY27 guidance of a 46% to 50% Australian EBITDA margin and $36 million to $40 million international EBITDA, as jackpots improved.

6 Nov, 9:29 am AEDT
ASX: MQGFinancials

Macquarie 1H27 Net Profit Up 50% to $A2,478 Million

Macquarie's 1H27 net profit was $A2,478 million, up 50 per cent on 1H26 and down 22 per cent on 2H26, with an interim dividend of $A3.25 per share, 35% franked.

6 Nov, 8:27 am AEDT
ASX: MYXHealth Care

Mayne Pharma to Sell International Segment for $55.5m

Mayne Pharma has agreed to sell Mayne Pharma International to Evaris Pharma for $55.5 million cash, subject to ACCC approval, to focus on the United States.

6 Nov, 8:52 am AEDT
ASX: NECCommunication Services

Nine Reaffirms FY27 Growth, Lifts Savings Target to $180m

Nine still expects FY27 revenue and EBITDA growth on a pro forma basis, with Q1 Total TV revenue down 6% and annualised savings now expected of at least $180m.

6 Nov, 9:15 am AEDT
ASX: PEBHealth Care

Pacific Edge Wins Medicare Coverage for Cxbladder Triage

Pacific Edge says the final Medicare LCD covers Cxbladder Triage and Triage Plus for intermediate risk microhematuria patients, effective 20 December 2026.

6 Nov, 7:30 am AEDT
ASX: QANIndustrials

Qantas Puts 1H27 Fuel Cost at About $3.75 Billion

Qantas says trading is in line with its FY26 outlook despite elevated fuel prices, and it now expects a 1H27 fuel cost of approximately $3.75 billion.

6 Nov, 8:43 am AEDT

Announcement summaries are published each trading day. General advice only.

Copyright © 2026 SureStone Capital